Related Experiment Videos
Update on therapeutic options for chronic myelogenous leukemia
M Talpaz1, H Kantarjian, R Kurzrock
1Department of Clinical Immunology, M.D. Anderson Cancer Center, Houston, TX 77030.
Seminars in Hematology
|July 1, 1990
Summary
Chronic myelogenous leukemia (CML) is a stem cell disorder. Interferon alfa treatment was introduced in 1981, offering a new therapeutic avenue for CML patients.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Chronic myelogenous leukemia (CML) is a myeloproliferative disorder originating from a stem cell mutation.
- CML progresses through distinct phases, including a chronic phase and a terminal blast crisis.
- Traditional treatments like chemotherapy and bone marrow transplantation have limitations in efficacy and patient eligibility.
Purpose of the Study:
- To introduce and evaluate interferon alfa as a novel treatment for Chronic Myelogenous Leukemia (CML).
Main Methods:
- Initiation of interferon alfa treatment for CML in 1981.
- Early studies utilized partially pure interferon alfa.
- Subsequent research employed interferon alfa-2a for CML treatment regimens.
Main Results:
- Interferon alfa emerged as a treatment option for CML, moving beyond conventional therapies.
- The evolution of interferon alfa preparations from partially pure to specific forms like alfa-2a was noted.
Conclusions:
- Interferon alfa represented a significant advancement in CML management starting in the early 1980s.
- The development of specific interferon alfa-2a formulations aimed to optimize CML treatment.